Arvinas Inc
NASDAQ:ARVN

Watchlist Manager
Arvinas Inc Logo
Arvinas Inc
NASDAQ:ARVN
Watchlist
Price: 18.73 USD 4.06%
Market Cap: 1.3B USD
Have any thoughts about
Arvinas Inc?
Write Note

Arvinas Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arvinas Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Arvinas Inc
NASDAQ:ARVN
Other Current Liabilities
$203.3m
CAGR 3-Years
8%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Other Current Liabilities
$4.8B
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
12%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Liabilities
$4.8B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
9%
Pfizer Inc
NYSE:PFE
Other Current Liabilities
$24.2B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
10%
Merck & Co Inc
NYSE:MRK
Other Current Liabilities
$7.2B
CAGR 3-Years
40%
CAGR 5-Years
24%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Other Current Liabilities
$5.6B
CAGR 3-Years
30%
CAGR 5-Years
21%
CAGR 10-Years
5%
No Stocks Found

Arvinas Inc
Glance View

Market Cap
1.3B USD
Industry
Pharmaceuticals

In the intricate world of biotechnology, Arvinas Inc. emerges as a pioneer, carving out a niche in the realm of targeted protein degradation. Founded by Dr. Craig Crews, the company stands at the forefront of innovation with its PROTAC® (PROteolysis TArgeting Chimeras) technology. This therapeutic approach cleverly harnesses the cell’s natural protein disposal system to degrade disease-causing proteins that have long evaded traditional drug targeting methods. By linking a target protein to an E3 ubiquitin ligase, PROTAC® molecules mark the unwanted proteins for cellular degradation, a strategy that potentially opens up a multitude of targets previously considered "undruggable." This inventive approach not only holds promise for treating a wide spectrum of diseases, including cancer and neurodegenerative disorders, but also positions Arvinas as a leader in redefining therapeutic paradigms. Focusing its business model on partnerships and collaborations, Arvinas has strategically aligned itself with some of the pharmaceutical industry's heavyweights. Revenue streams are derived from these collaborations, which include potential milestone payments, option fees, and royalties linked to the successful commercialization of therapeutics developed through its proprietary PROTAC® technology. By leveraging strategic alliances, Arvinas not only amplifies its research capabilities but also diversifies financial risk. The company is thus uniquely positioned at the intersection of science and commerce, driving innovation while capitalizing on its cutting-edge platform. This dual focus on robust scientific exploration and strategic financial growth creates a compelling narrative for a biotech company aiming to revolutionize disease treatment.

ARVN Intrinsic Value
11.57 USD
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Arvinas Inc's Other Current Liabilities?
Other Current Liabilities
203.3m USD

Based on the financial report for Sep 30, 2024, Arvinas Inc's Other Current Liabilities amounts to 203.3m USD.

What is Arvinas Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
59%

Over the last year, the Other Current Liabilities growth was -10%. The average annual Other Current Liabilities growth rates for Arvinas Inc have been 8% over the past three years , 59% over the past five years .

Back to Top